Related Experiment Video
Updated: Jul 19, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Breast cancer expression profiling: the impact of microarray testing on clinical decision making
Olga Modlich1, Hans-Bernd Prisack, Hans Bojar
1Institut für Onkologische Chemie, University of Düsseldorf, Universitätsstrasse 1, D-40225, Düsseldorf, Germany. omodlich@onkochemie.uni-duesseldorf.de
Expert Opinion on Pharmacotherapy
|October 6, 2006
Summary
Clinical prognostic tools and pathological features have limitations in predicting breast cancer outcomes. While molecular profiling shows promise, it currently cannot outperform standard diagnostics for breast cancer patient risk prediction.
Area of Science:
- Oncology
- Genomics
- Biomarkers
Background:
- Clinical prognostic tools and pathological features exhibit limitations in accurately predicting breast cancer patient outcomes.
- Established criteria and prognostic tools like Nottingham Prognostic Index (NPI) and Adjuvant-Online have theoretical limitations.
- Molecular classification using gene expression panels is proposed as a superior alternative for risk prediction and treatment outcomes.
Purpose of the Study:
- To review the practical challenges and limitations in applying molecular profiling for breast cancer clinical purposes.
- To evaluate the current performance of molecular classification and forecasting against standard tumor diagnostics.
Main Methods:
- Review of existing literature on clinical prognostic tools, pathological features, and molecular profiling in breast cancer.
- Analysis of the theoretical advantages and practical limitations of gene expression profiling.
- Comparison of commercially available gene expression-based diagnostic tests with standard tumor diagnostics.
Main Results:
- Current clinical prognostic tools and pathological features are insufficient for accurate breast cancer outcome prediction.
- Microarray-based molecular classification is theoretically superior but faces practical application challenges.
- Existing molecular profiling diagnostic tests do not currently outperform standard tumor diagnostics in breast cancer forecasting.
Conclusions:
- Despite theoretical advantages, molecular profiling of breast cancer faces significant practical hurdles for clinical implementation.
- Further research and development are needed to overcome current limitations and improve the clinical utility of molecular diagnostics in breast cancer.
